Prometrium Standard Titration Schedule: What Every Woman Needs to Know

What Is the Standard Prometrium Titration Schedule?

The standard titration starts at 100 mg taken orally at bedtime, then moves to 200 mg at bedtime after 4 to 12 weeks if you are tolerating the lower dose well and your clinical goal has not been met. For endometrial protection in menopausal hormone therapy, the FDA-approved dose is 200 mg nightly for 12 days per 28-day cycle, or 100 mg nightly continuously when combined with daily estrogen. Doses above 200 mg are used off-label and require a clear clinical rationale.

The word "titration" here means two different things depending on context. For menopausal hormone therapy, it refers to moving between a protective cycling dose and a continuous daily dose. For luteal-phase support, sleep, or PCOS-related cycle regulation, it refers to finding the lowest effective nightly dose. These are not interchangeable protocols.

Why Bedtime Dosing Is Non-Negotiable

Micronized progesterone reaches peak serum concentration roughly 1 to 3 hours after an oral dose. That peak coincides with significant sedation and, in some women, dizziness. Taking Prometrium in the morning or afternoon produces the same sedation at a time when you are driving or working. Every clinical protocol, including the prescribing information, specifies bedtime dosing. This is not a preference. It is a pharmacokinetic safety requirement.

The Role of Food

Taking Prometrium with a high-fat snack increases oral bioavailability approximately threefold compared with fasting. That matters during titration because the same 100 mg dose can behave very differently on an empty stomach versus after a snack. To get consistent, predictable serum levels across your titration, take it the same way every night, either always with a small fat-containing snack or always fasting.

How the Titration Differs by Life Stage

Progesterone physiology changes dramatically across a woman's life. A 42-year-old in perimenopause, a 55-year-old two years past her last period, and a 32-year-old with PCOS are all candidates for Prometrium, but their titration schedules, targets, and monitoring plans look nothing alike.

Reproductive Years (Ages Roughly 18 to 40)

Women in their reproductive years most often receive Prometrium for cycle regulation, luteal phase deficiency, or PCOS. The standard starting dose for cycle regulation is 100 mg orally at bedtime for 12 days per cycle. Many clinicians start here and do not escalate unless symptoms persist after two to three cycles at 100 mg.

For PCOS specifically, the goal is usually to induce a withdrawal bleed and oppose any endometrial buildup from unopposed estrogen. The ASRM Practice Committee recommends progestogen challenge or cyclic progestin use to protect the endometrium when cycles are irregular. Prometrium 100 mg for 12 days per month is a reasonable starting point. If the bleed is inadequate or symptoms persist, a move to 200 mg for 12 days is appropriate at the next cycle.

Perimenopause (Typically Ages 40 to 52)

Perimenopause is where titration gets genuinely complex. Your progesterone levels swing unpredictably, your cycle length varies, and you may have both estrogen excess (from anovulatory cycles) and progesterone deficiency happening in the same month. Vasomotor symptoms, heavy bleeding, and sleep disruption can all be present simultaneously.

For perimenopausal women who still have a uterus and are starting systemic estrogen therapy, The Menopause Society (NAMS) 2023 Position Statement recommends adding a progestogen to protect the endometrium. A common approach is to start at Prometrium 100 mg nightly continuously, or 200 mg for 12 to 14 days of each calendar month if a cycling schedule is preferred. Because perimenopause brings erratic endogenous progesterone, continuous low-dose (100 mg) is often better tolerated than a cycling regimen that layers exogenous progesterone on top of a spontaneous luteal phase.

Titration in this group often means adjusting the schedule (cycling vs. Continuous) rather than simply increasing milligrams. If sleep disruption is the primary complaint and vasomotor symptoms are mild, 100 mg nightly continuously is often sufficient without ever escalating to 200 mg.

Post-Menopause (More Than 12 Months Since Last Period)

Post-menopausal women taking systemic estrogen therapy need endometrial protection at every dose of estrogen. The PEPI trial (JAMA, 1995) demonstrated that micronized progesterone 200 mg per day for 12 days per month provided endometrial protection equivalent to medroxyprogesterone acetate (MPA) while showing a more favorable effect on HDL cholesterol than MPA. This remains one of the key pieces of evidence distinguishing micronized progesterone from synthetic progestins in terms of cardiometabolic profile.

The standard post-menopausal titration is:

• Continuous regimen: 100 mg nightly every night, combined with daily estrogen
• Sequential regimen: 200 mg nightly for 12 to 14 consecutive days per month

Most clinicians start post-menopausal women at 100 mg nightly for 4 to 8 weeks and move to 200 mg (or switch to a cycling schedule) only if breakthrough bleeding or inadequate symptom control occurs.

Sex-Specific Pharmacokinetics: Why Women Absorb Progesterone Differently

This section matters because most pharmacokinetic data for Prometrium was gathered in post-menopausal women receiving concomitant estrogen therapy. If you are younger, cycling, or not taking estrogen, your absorption and metabolism will differ.

Estrogen Status Changes Absorption

Oral micronized progesterone is almost entirely first-pass metabolized in the liver and gut wall. Serum progesterone after 200 mg oral Prometrium in fasted post-menopausal women is roughly 17 ng/mL at peak, which is modest. Co-administration of estrogen increases binding proteins and may subtly alter the distribution of progesterone metabolites. The neurosteroid metabolites, particularly allopregnanolone, produced during hepatic first-pass metabolism are the primary driver of sedation. Women with higher baseline estrogen (perimenopausal, cycling, or on estrogen therapy) produce slightly different metabolite ratios.

Cycle Phase Matters in Pre-Menopausal Women

If you are still cycling and adding exogenous Prometrium in your luteal phase, you are layering it on top of your own corpus luteum output. Your endogenous progesterone in a normal luteal phase ranges from 5 to 20 ng/mL. Adding 100 mg oral Prometrium to that raises total progesterone exposure substantially. This is why pre-menopausal women often experience more pronounced sedation at the same milligram dose than post-menopausal women do.

Body Composition

Progesterone is highly lipophilic. Higher body fat percentage can increase the volume of distribution, potentially blunting peak serum levels and extending the half-life. There are no large-scale women-specific PK studies stratifying by body composition for Prometrium. This is an evidence gap you should know about. Dosing in women with obesity is currently extrapolated from post-menopausal trial data rather than directly studied. If you have a BMI <18.5 or >35 and are titrating Prometrium, discuss this directly with your clinician, as standard doses may overshoot or undershoot your target.

The Slow-Titration Approach: When to Take More Time

Most published protocols treat Prometrium titration as a binary choice: 100 mg or 200 mg. In clinical practice with women who are highly sensitive to neurosteroid metabolites, a slower ramp is sometimes used. The WomanRx clinical team uses the following framework when a patient reports intolerable sedation, dizziness, or mood changes at 100 mg:

1. Weeks 1 to 2: 100 mg every other night at bedtime (off-label, used to assess baseline sensitivity)
2. Weeks 3 to 6: 100 mg nightly at bedtime if every-other-night is tolerated
3. Weeks 7 to 14: 200 mg nightly if 100 mg is tolerated and clinical goal requires escalation

This slower ramp is not described in the FDA prescribing information and is not supported by a dedicated RCT. It is based on the pharmacokinetic principle that allopregnanolone accumulation drives early-dose side effects, and that allowing the GABAergic system a longer adaptation window reduces dropout. Women with a history of PMDD, benzodiazepine sensitivity, or alcohol sensitivity are the most likely candidates for this slower approach.

How Quickly Can You Increase Prometrium?

This is the question most women ask once they start. The honest answer is that the minimum interval before escalating is determined by two things: symptom response and side-effect clearance.

Side effects from Prometrium, particularly sedation and dizziness, tend to peak in the first one to two weeks at any new dose and then diminish as your neurosteroid receptors adapt. A 2014 review in the journal Menopause noted that GABA-A receptor modulation by allopregnanolone is the central mechanism of sedation, and that receptor downregulation occurs within two to four weeks of consistent dosing.

For most women, a 4-week minimum at a new dose before escalating is appropriate. For women with significant neurosteroid sensitivity (PMDD history, alcohol sensitivity, prior benzo use), 8 to 12 weeks at 100 mg before moving to 200 mg is more appropriate. Escalating sooner than 4 weeks rarely produces better outcomes and often produces worse tolerability.

There is no evidence that going from 100 mg to 200 mg in one step causes harm in otherwise healthy women without a peanut allergy. The concern is tolerability, not toxicity.

Prometrium for Sleep: Is Dose Titration Different?

Prometrium is used off-label for sleep in perimenopausal and post-menopausal women. The sedating metabolite allopregnanolone is a potent positive allosteric modulator of GABA-A receptors. A randomized trial by Caufriez et al. (2011) in Menopause found that 300 mg oral micronized progesterone nightly significantly improved sleep architecture compared with placebo in post-menopausal women.

For sleep-specific use, some clinicians titrate:

• Start at 100 mg nightly for 4 weeks
• Move to 200 mg if sleep improvement is incomplete
• Consider 300 mg (off-label) only if 200 mg produces no meaningful improvement and is well-tolerated

300 mg nightly is above the FDA-approved dose range for hormone therapy indications. If your clinician prescribes it for sleep, confirm they are aware of the off-label status and that you have had a baseline endometrial evaluation if you are post-menopausal with a uterus.

Prometrium and PCOS

Women with PCOS face a specific challenge: they often have chronically elevated estrogen from constant aromatization of androgens, minimal progesterone production due to anovulation, and significant endometrial exposure over months or years. The ASRM recommends that women with oligomenorrhea or amenorrhea from PCOS receive progestin therapy to induce regular withdrawal bleeds and reduce endometrial cancer risk.

The typical Prometrium schedule for PCOS cycle regulation is 100 mg nightly for 12 consecutive days per month. If no withdrawal bleed occurs within 10 days of completing the course, this may indicate either inadequate endometrial priming (too little estrogen) or an endometrial abnormality, and further evaluation is warranted before escalating dose. Simply increasing to 200 mg without a clinical explanation for the absent bleed is not appropriate.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age.

Pregnancy Safety

The FDA removed letter pregnancy categories in 2015. Micronized progesterone does not carry a single letter grade anymore. What the evidence shows is more nuanced.

Prometrium is used therapeutically in early pregnancy, primarily for luteal phase support in assisted reproduction and, increasingly, for threatened miscarriage in women with a history of recurrent pregnancy loss. The PRISM trial (New England Journal of Medicine, 2019) found that vaginal micronized progesterone 400 mg twice daily in women with early pregnancy bleeding and a history of prior miscarriage resulted in a live birth rate of 65.8% versus 63.3% in the placebo group, a difference that did not reach statistical significance in the overall cohort but did suggest benefit in women with a history of three or more prior losses.

The oral Prometrium formulation is not the standard of care for pregnancy support. Vaginal progesterone is preferred for pregnancy indications because it achieves higher local uterine concentrations with lower systemic exposure. If you are pregnant or trying to conceive, do not substitute oral Prometrium for a vaginally prescribed progesterone product without direct clinician guidance.

Prometrium capsules contain peanut oil. The FDA prescribing information explicitly states that Prometrium is contraindicated in women with peanut allergy. This applies during pregnancy as well.

Lactation

Progesterone is a naturally occurring hormone and is present in breast milk. The clinical concern with exogenous progesterone supplementation during lactation is that it may suppress prolactin-mediated milk production, particularly at doses above physiological replacement levels. There are no large controlled studies of oral Prometrium use during lactation. The LactMed database (NIH) notes that progestogens in low doses have not been shown to significantly impair established lactation after six weeks postpartum, but data specific to micronized progesterone at doses of 100 to 200 mg orally are limited.

If you are breastfeeding and your clinician recommends Prometrium, discuss the timing of dosing relative to feeding. Taking it immediately after the last nighttime feed and before your longest sleep stretch minimizes infant exposure through milk.

Contraception Requirement

Prometrium used for hormone therapy in post-menopausal women does not provide contraception. Perimenopausal women can still ovulate sporadically and remain at risk for unintended pregnancy until 12 consecutive months of amenorrhea have passed. ACOG Practice Bulletin No. 141 notes that menopausal hormone therapy products should not be relied upon for contraception.

If you are perimenopausal, cycling irregularly, and starting Prometrium for hormone therapy, you need a concurrent contraceptive method unless pregnancy is acceptable to you.

Who Is a Good Candidate for Prometrium, and Who Is Not?

Likely to Benefit

• Post-menopausal women on systemic estrogen therapy who need endometrial protection
• Perimenopausal women with heavy irregular cycles and documented estrogen exposure
• Women with PCOS and amenorrhea who need cycle regulation and endometrial protection
• Women with sleep disruption in perimenopause or menopause who prefer a non-synthetic progestogen
• Women who have had intolerable side effects with medroxyprogesterone acetate (MPA) and want a bioidentical alternative

Not a Good Candidate

• Women with a peanut allergy (absolute contraindication)
• Women with a history of or current breast cancer, particularly hormone receptor-positive (Prometrium is a progestogen and its use in this population requires oncology input)
• Women with unexplained vaginal bleeding (evaluate first, treat second)
• Women who are pregnant and need progesterone support for an obstetric indication (use vaginal formulations as directed, not oral Prometrium)
• Women with active liver disease (extensive first-pass hepatic metabolism makes dosing unreliable and may worsen liver stress)
• Women who cannot tolerate bedtime-only dosing due to schedule or sleep-disorder constraints that make consistent administration difficult

Monitoring During Titration

There is no validated serum progesterone level target for oral Prometrium therapy. Serum progesterone drawn after oral dosing reflects a mix of parent compound and neurosteroid metabolites, and the correlation between serum level and endometrial protection is poor for oral routes. Unlike vaginal or injectable progesterone, oral progesterone monitoring by serum level is not clinically useful for dose adjustment.

What you should monitor instead:

• Endometrial thickness: A baseline transvaginal ultrasound before starting, and repeat annually or sooner if you experience unexpected bleeding, is appropriate for any woman with a uterus on estrogen plus progestogen therapy
• Symptom diary: Track sleep quality, vasomotor symptoms, bleeding pattern, and mood in the first 12 weeks of each dose change
• Side effects: Report persistent dizziness, depression, or changes in libido to your clinician before escalating dose, not after

The Menopause Society recommends annual clinical follow-up for women on menopausal hormone therapy, with reassessment of the risk-benefit ratio at each visit.

Side Effects That Appear During Titration and What to Do

| Side Effect | When It Peaks | Action | |---|---|---| | Sedation / "progesterone drowsiness" | Week 1 to 2 at each new dose | Confirm bedtime dosing; wait 2 to 4 weeks for adaptation | | Dizziness | Week 1 to 2 | Take with small fat-containing snack; stay lying down 30 minutes post-dose | | Breast tenderness | Variable; may worsen at 200 mg | Usually resolves; if persistent after 8 weeks, reassess need for dose increase | | Mood changes / low mood | Days 3 to 10 at new dose | Track with diary; women with PMDD history are at higher risk | | Irregular spotting | First 3 months of continuous regimen | Expected; persistent or heavy bleeding warrants endometrial evaluation | | Headache | Variable | Often resolves; if new or severe, rule out vascular cause |

Sedation is the most common reason women discontinue Prometrium during titration. The solution is almost always better timing and consistency, not dose reduction. Take it within 30 minutes of lying down to sleep. Every time.